Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen

NCT01622062 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Rabies

Interventions

BIOLOGICAL: PVRV
BIOLOGICAL: PVRV and pERIG Favirab®
BIOLOGICAL: PVRV and pERIG Favirab®

Sponsor

Sanofi Pasteur, a Sanofi Company